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Abstract
Background: Chromosome abnormalities, especially trisomy of chromosome 21, 13, or 18 as well as sex
chromosome aneuploidy, are a well-established cause of pregnancy loss. Cultured cell karyotype analysis and FISH
have been considered reliable detectors of fetal abnormality. However, results are usually not available for 3-4 days
or more. Multiplex ligation-dependent probe amplification (MLPA) has emerged as an alternative rapid technique
for detection of chromosome aneuploidies. However, conventional MLPA does not allow for relative quantification
of more than 50 different target sequences in one reaction and does not detect mosaic trisomy. A multiplexed
MLPA with more sensitive detection would be useful for fetal genetic screening.
Methods: We developed a method of array-based MLPA to rapidly screen for common aneuploidies. We designed
116 universal tag-probes covering chromosomes 13, 18, 21, X, and Y, and 8 control autosomal genes. We
performed MLPA and hybridized the products on a 4-well flow-through microarray system. We determined
chromosome copy numbers by analyzing the relative signals of the chromosome-specific probes.
Results: In a blind study of 161 peripheral blood and 12 amniotic fluid samples previously karyotyped, 169 of 173
(97.7%) including all the amniotic fluid samples were correctly identified by array-MLPA. Furthermore, we detected
two chromosome X monosomy mosaic cases in which the mosaism rates estimated by array-MLPA were basically
consistent with the results from karyotyping. Additionally, we identified five Y chromosome abnormalities in which
G-banding could not distinguish their origins for four of the five cases.
Conclusions: Our study demonstrates the successful application and strong potential of array-MLPA in clinical
diagnosis and prenatal testing for rapid and sensitive chromosomal aneuploidy screening. Furthermore, we have
developed a simple and rapid procedure for screening copy numbers on chromosomes 13, 18, 21, X, and Y using
array-MLPA.
Background
Chromosome abnormalities are a well-established cause
of pregnancy loss. The most common are autosomal
aneuploidy (~75%), followed by polyploidy (~13%), sex
chromosome abnormalities (~8%) and structural imbal-
ance (~4%) [1,2]. Trisomy of chromosome 21, 13, or 18
as well as sex chromosome aneuploidy account for 60-
80% of abnormal fetal karyotypes detected in cultured
amniotic fluid cells [3].
For non-mosaic standard trisomy, cultured karyotype
analysis has been considered a reliable detector of fetal
abnormality [4]. However, the sensitivity of karyotyping
depends on the number of cells established in a particu-
lar culture, and results are usually not available for 3-4
days or more. Furthermore, it is very difficult to identify
chromosome microdeletions. In addition to karyotype
analysis, fluorescence in situ hybridization (FISH), an
easy-to-handle, rapid, and highly sensitive tool for
genetic analysis, has been developed in the past two dec-
ades [5-14]. Recently, AneuVysion FISH analysis has
become the most common rapid screening method for
prenatal or neonatal aneuploidies in a clinical setting. In
most laboratories, AneuVysion analysis for prenatal test-
ing costs between $300 and $350. However, FISH is
labor-intensive and not easily applicable to a large num-
ber of samples in clinical diagnostic settings.
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Multiplex quantitative fluorescence PCR (QF-PCR)
provides the possibility to detect copy number variation
of chromosomal sequences in several hours [12,15-19].
It also has the advantage of being much cheaper and
allowing the simultaneous processing of larger numbers
of samples than FISH and karyotyping analysis. How-
ever, the presence of multiple primer pairs in a PCR
reaction reduces the reliability of the quantification. To
solve these technical problems, multiplex ligation-depen-
dent probe amplification (MLPA) has emerged as an
alternative to standard PCR-based techniques for detec-
tion of the chromosome aneuploidies [20-22]. It allows
for relative quantification of up to 50 different target
sequences in one reaction and does not require living
cells or cell culture. It is less labor-intensive and less
expensive compared to karyotyping and FISH. There-
fore, MLPA has been widely applied for molecular diag-
nosis of genetic diseases such as DMD, Spinocerebellar
ataxia type 15 and chromosomal aneuploidies
[21,23-26]. Moreover, a commercial MLPA kit based on
length discrimination of the ligation products for detec-
tion of aneuploidies on chromosomes 13, 18, 21, X and
Y has been developed. Its turn-around time can be as
rapid as 30 hours.
A primary drawback of MLPA is its dependence on
length-based discrimination of the ligation products. To
differentiate between amplification products, the probes
contain a non-hybridizing stuffer sequence of variable
length. Therefore, MLPA limits the number of probes to
50 pairs or fewer. The size differences complicate the
essential quantitative PCR step, since smaller fragments
are amplified more efficiently. To resolve these technical
hurdles, we have recently developed a universal flow-
through array to quantify the MLPA amplification pro-
ducts, and successfully applied the array-MLPA assay
for detection of deletions and duplications in Duchenne
muscular dystrophy patients [27].
To determine whether the array-MLPA format can be
used in clinical diagnostic settings to screen for com-
mon aneuploidies, we performed array-MLPA analysis
on 161 peripheral blood and 12 amniotic fluid samples.
Moreover, we confirmed the genotypes obtained on
array-MLPA by G-banded karyotype analysis.
Methods
Patient materials
The peripheral blood samples were collected from 76
unrelated patients and 85 healthy individuals from
Shanghai Children’s Hospital. Twelve amniotic fluid
samples (15-20 ml/sample) without blood contamination
were obtained from the Institute of Medical Genetics in
Henan Provincial People’s Hospital. The amniotic fluid
samples were collected from cases with abnormal mater-
nal serum screening results. Informed consent was
obtained from each participant. The study was approved
by the ethics committee of Shanghai Children’s Hospital.
Genomic DNA was extracted from peripheral blood or
amniotic fluid cells (5 ml/sample) using the phenol/
chloroform method. The concentration and quality of
the DNA was estimated by measuring the optical den-
sity (OD) at 260 nm and 280 nm using a spectrophot-
ometer (DU800, Beckman, US). Each sample was
checked on gel electrophoresis. A DNA sample was dis-
carded for further analyses if OD 260/280 ratio was not
within the normal range (1.8-2.0). Additionally, the con-
centration of each DNA sample was standardized to 100
ng/μL. The data processing of the array-MLPA tests
were performed without the knowledge of karyotype
results.
MLPA probe design and reaction
The design of the assay probes was essentially as
described for array-MLPA [27]. The target sequences on
chromosomes 13, 18, 21, X and Y were designed using
the Ensembl genome browser (http://www.ensembl.org).
Additionally, the target sequences of 8 autosomal genes
on chromosomes 2, 4, 5, 11, 12, and 15 were designed
as control probes. Ultimately, 116 pairs of MLPA probes
covering chromosomes 13 (probe n = 28), 18 (probe n =
26), 21 (probe n = 22), X (probe n = 22), Y (probe n =
10) and 8 control probes were included in the study.
The accession numbers and probe sequences are shown
in Additional file 1, Table S1.
All of the oligonucleotides were chemically synthe-
sized (Illumina, CA, USA) in a salt-free environment (25
nmol scale) and used without further purification. The
probe mix was prepared at a final concentration of 4
nM per probe. MLPA reagents were purchased from
MRC-Holland (Amsterdam, The Netherlands). The
MLPA reaction was performed using a standard proto-
col described previously [27].
Universal flow-through array and hybridization
In this study, a 4-well universal flow-through array with
124 pairs of 20-mer oligonucleotide tag-probes was used
(PamGene, Den Bosch, The Netherlands). The prepara-
tion of the array using a porous aluminum-oxide sub-
strate was performed as previously described [27-29]. In
each of the arrays up to 400 probes can be spotted on
the substrate. In comparison with two-dimensional geo-
metry, the reactive surface in the porous substrate is
increased approximately 500-fold. During hybridization,
samples are actively pumped back and forth through the
porous structure, resulting in a hybridization time of 5-
30 minutes. Schematic depiction of the array technology
is shown in Additional file 2, Figure S1.
The array hybridization was performed using a stan-
dard protocol described previously [27]. A single chip
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contained 4 identical arrays. One normal control and
three other samples were analyzed in parallel. After
washing the arrays, images were recorded at 500 ms,
1000 ms, 1500 ms and 3000 ms exposure time using a
Cy5 filter set. Additionally, three independent experi-
ments for each of 30 normal control individuals (15
males and 15 females) were performed to determine the
accuracy of array-MLPA and the distributions of the
normal copy numbers.
Data analysis
Each array image was converted into spot intensity
values using BioNavigator software (PamGene, Den
Bosch, The Netherlands). Pixel-by-pixel cross-correla-
tion was used to segment signal, background and arti-
fact pixel populations. Median signal intensities were
obtained for each spot on the array and local back-
ground was subtracted. A cutoff value for a positive sig-
nal was defined as three times above the standard
deviation (SD) of the background. The mean signal of
duplicate spots on each array was normalized using the
mean signal of the eight control autosomal genes. Copy
numbers of chromosomes 13, 18, 21, X and Y were
computed as the ratio of test signal to autosomal con-
trol signal for each sample. The copy number data were
exported into Microsoft Excel (Microsoft, Redmond,
WA), where the median, SD and coefficients of variation
(CV) of these chromosomes were calculated.
Normal copy number values for chromosomes 13, 18,
21 and X were defined between 0.85 and 1.15 in normal
females, whereas the normal values of chromosomes X
and Y were defined between 0.35 and 0.65 in normal
males. Chromosomal trisomy was considered if the copy
number was measured as 1.35 to 1.65 in a sample. The
XXY type was detected if the copy number of chromo-
some X ranged from 0.85 to 1.15. When the ratio was
below 0.65 in female patients, Turner’s syndrome was
identified. Samples that showed an average CV above
15% were considered to be unreliable.
Karyotype analysis
Peripheral blood cells or amniotic fluid cells (10-15 ml/
sample) were cultured according to the standard techni-
ques on culture slides followed the method described by
ISCN [28]. G banding was used for analysis and more
than 20 metaphase chromosomes were routinely investi-
gated. The results derived from array-MLPA and karyo-
typing were compared.
Deletion confirmation
Y-chromosome-specific PCRs for SRY, TSPY, RBMY
genes were performed to confirm deletions on the
mosaic samples detected by array-MLPA. The primer
sequences are listed in Table 1. The PCR reaction con-
ditions were 95°C, 5 min followed by 33 cycles of 95°C,
1 min, 60°C, 1 min (55°C for TSPY gene) and 72°C, 2
min along with final extension at 72°C for 10 min. The
PCR product was then subjected to 1% agarose gel for
electrophoretic separation.
Results
Array-MLPA is not a length-based discrimination
method, which can overcome the main drawback of
MLPA. The sensitivity and specificity of array-MLPA is
based on the universal flow-through array hybridization
and data analysis. To determine the reliability of array-
MLPA, 30 normal control individuals (15 males and 15
females) were first tested with replicate measurements.
The mean standard deviation across the 30 control indi-
viduals was 0.024, indicating the low inter-individual
variability on the array-MLPA test. All probes designed
on chromosomes 13, 18, 21 and X of female samples
had an average relative signal of about 1.0, whereas the
average signal of chromosomes X and Y in males was
approximately 0.5. The copy numbers of almost all the
controls were located within the normal distributions (
two grey lines in Figure 1). The intra-assay standard
deviations of the probe signals on chromosome 13, 18,
21, X and Y ranged from 0.018 to 0.031. Examples of
the copy numbers on array-MLPA for a normal female
and a normal male are shown in Figure 2. The average
gene copy numbers on the five chromosomes in the
normal controls are listed in Additional file 3, Table S2.
Overall, 89.4% of the relative probe signals in the nor-
mal controls were within the normal range (0.85 to
1.15).
Next, array-MLPA was performed on 161 peripheral
blood and 12 amniotic fluid samples including the 30
Table 1 PCR primers for deletion confirmation
Gene Primer sequence Annealing Temperature (°C) PCR product length (bp)
SRY 5’-GAGACTCAGACAGCGAAGTA-3’ 60 3155
5’-ACGTCCAGGATAGAGTGAAG-3’
TSPY 5’-TTACCTCCGTACCATCTACC-3’ 55 3396
5’-GAAGTCAGCCTCCAACTAAG-3’
RBMY 5’-CCGTTATCCTCTTCAGTCAC-3’ 60 3174
5’-CATCTAGAGGCCATGCATAC-3’
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normal controls described above. Karyotype analysis was
independently carried out on these samples. The results
obtained by array-MLPA and the corresponding G-
banded karyotypes were presented in Table 2. Of 173
tested samples, 169 (97.7%) including 12 amniotic fluid
samples were correctly identified by array-MLPA. Figure
3 showed the abnormal copy numbers on chromosome
21 or X for two fetus samples. One was a male fetus
(A9) in which the average copy number of chromosome
21 reached 1.53 indicating trisomy 21 (Figure 3A), while
another was a male fetus (A10) in which the copy num-
ber on the X chromosome was 0.85 ±0.02 suggesting
XXY (Figure 3B). However, four abnormal karyotypes
including 46,XX,-14,+t(14;21);(p11.2;p11.2); 46,XY,rec
(14)(18qter®18q22::14qter)pat; 46,XY,inv(9)(p12q21)
and 46,XY,t(1;7)(p36.3;p13) could not be detected by
array-MLPA (Table 2). A comparison of the results
from array-MLPA and karyotyping was summarized in
Table 3.
In this study, two cases (B10 and B11) with chromo-
some X monosomy mosaicism were identified success-
fully by array-MLPA (Table 2). For mosaic samples, the
ratio reflects the extent of mosaicism, e.g. ratio 0.75 for
a 50% chromosome X monosomy in a female sample.
The results showed that the average copy numbers of
chromosome X were 0.71 and 0.72 in the two samples.
Figure 1 Array-MLPA analysis of normal controls (15 normal females and 15 normal males). The average copy numbers on chromosomes
13, 18, 21, X and Y were shown in A, B, C, D and E, respectively. The normal distributions of copy number in the control individuals were shown
with two grey lines. Error bars represented the corresponding standard deviation (SD) of the copy numbers for the MLPA probes covering each
chromosome.
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This suggested that approximately 50% of the sample
cell population carried chromosome X monosomy. G-
banded karyotype analysis showed that their chromo-
some karyotypes were 45,X/46,X,i(X)(q10) and 45,X/47,
XXX for B10 and B11 respectively, which were basically
consistent with array-MLPA results (Figure 4).
Additionally, five cases (B5-B9) with exceptive sex
chromosome aneuploidies were identified using the cri-
terion that at least four of ten Y chromosome-specific
probes detected an abnormality. The probe signals in
the TSPY gene were identified in all of the five cases
(B5-B9). While the signals in the RBMY gene were
detected in three samples (B7-B9). Subsequently, the G-
banding analysis revealed that they were chromosome X
monosomy mosaics with chromosome Y or unknown
marker chromosome (mar) (Table 2). Their karyotypes
were 45,X/45,X, mar for samples B5-B6, 45,X/46,XY for
the sample B7 and 45,X/46,XY(Yq-) for samples B8-B9,
respectively. PCR analysis of the RBMY, SRY and TSPY
genes confirmed that the unknown marker chromosome
found in samples B5 and B6 was indeed a part of chro-
mosome Y (Figure 5).
Discussion
Trisomy of chromosome 21, 13, or 18 as well as sex
chromosome aneuploidy are the main genetic diseases
Figure 2 A normal female and normal male were analyzed with array-MLPA. The left figures showed the relative signal of each probe. The
probes on chromosomes 13, 18, 21, X and Y were depicted in yellow, blue, green, purple and purplish red, respectively. Eight autosomal control
probes were shown in grey. The right figures showed the average copy numbers on each chromosome. Error bars represented the
corresponding SD of the copy numbers on the MLPA probes covering each chromosome. The copy number of each chromosome was listed in
the lower tables. In the female, the copy numbers on chromosomes 13, 18, 21 and X were defined between 0.85 and 1.15. In the male, the
copy numbers on chromosomes 13, 18 and 21 were nearly 1, while the copy numbers on chromosomes X and Y were approximately 0.5.
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of newborns. So far, there is no effective treatment for
these diseases. Therefore, it is crucial to develop a rapid,
reliable and highly sensitive molecular diagnostic techni-
que. In this study, a 4-well universal flow-through array
based on a three-dimensional aluminum-oxide substrate
was used to analyze MLPA amplification products
(array-MLPA). The main advantages of array-MLPA
over other techniques such as karyotype analysis, FISH
and multiplex PCR, are its simplicity, speed, and analysis
of 124 detector probes in parallel. Four different samples
for 124 genetic markers can be tested all at once within
6 hours starting from fresh blood or amniotic fluid sam-
ples. The cost of the universal chip is limited to $50 per
sample. An additional advantage of this method is the
automated measurement and data analysis. Compared to
AneuVysion FISH analysis, the array-MLPA system
demonstrates at least 4-fold shorter assay time and at
least 6-fold less assay cost. The reproducibility and accu-
racy of the array technology were demonstrated pre-
viously in studies on gene expression profiling [29,30]
and quantification of PMP22 gene copy number [31]
and detection of DMD genomic rearrangements [27].
To further investigate the applicability of array-MLPA
for rapid chromosomal aneuploidy screening, especially
in fetuses at risk for Down’s syndrome, we performed
array-MLPA analysis on 161 peripheral blood and 12
amniotic fluid samples. Our results showed that 169 of
173 (97.7%) samples including all the amniotic fluid
samples identified by array-MLPA were concordant with
karyotype analysis. Our study demonstrates the success-
ful application and strong potential of array-MLPA in
clinical diagnosis and prenatal testing for rapid chromo-
somal aneuploidy screening. Further validation studies
must be performed to ensure the clinical applicability of
our array-MLPA assay.
To improve the reliability of detection, we designed
two different probes per targeted gene, located in the 5’
and 3’ region of the same gene, and the average values
of two probes were used to calculate the copy number
of the gene. The data indicated that 89.4% of the relative
probe signals from array-MLPA ranged from 0.85 to
1.15 in the normal controls. In the previous MLPA ana-
lysis [26], the normal region was usually set defined as
0.7 to 1.3. This indicates that array-MLPA is more accu-
rate than the reported results with conventional MLPA
for the determination of copy number.
It is well-known that intrinsic sensitivity limitations of
MLPA make it unsuitable for reliable detection of
mosaicism. It has become possible to detect the mosai-
cism of chromosomal aneuploidies by array-MLPA due
to its higher accuracy. In this study, we identified sex
chromosome mosaicism in two patients by array-MLPA.
In one case (B10), the average copy number on chromo-
some X was 0.71 revealing approximately 50% mosaic
rate of chromosome X. The result was concordant with
that of conventional cytogenetic analysis. In another
case (B11), a similar result was observed on array-
MLPA. However, G-banded karyotype analysis indicated
the chromosome karyotypes 45,X(70%)/47,XXX(30%).
The result showed that there were polyploid cells in the
patient B11. This suggests array-MLPA might have a
bias in detection. Array-MLPA appeared to be more
Table 2 Summary of the results of array-MLPA and karyotype analysis
Sample ID Array-MLPA Karyotype Sample type
N1-N53 Normal 13, 18, 21, X, Y 46,XY
N54-N85 Normal 13, 18, 21, X 46,XX
B1-B4 Monosomy X 45,X
B5-B6 Monosomy X+TSPY signals 45,X/45,X,+mar?
B7 Monosomy X+RBMY, TSPY signals 45,X/46,XY
B8-B9 Monosomy X+ RBMY, TSPY signals 45,X/46,XY(Yq-?)
B10 Abnormal monosomy X (XR = 0.71) 45,X/46,X,i(X)(q10)
B11 Abnormal monosomy X (XR = 0.72) 45,X/47,XXX Blood
B12-B29 Trisomy 21 (21R = 1.36 to1.62) 47,XX,+21
B30 Normal 13, 18, 21, X, Y 46,XY,rec(14)(18qter®18q22::14qter)pat
B31-B72 Trisomy 21 (21R = 1.37 to1.56) 47,XY,+21
B73 Male with extra X 47,XXY
B74 Normal 13, 18, 21, X 46,XX,-14,+t(14;21);(p11.2;p11.2)
B75 Normal 13, 18, 21, X, Y 46,XY,inv(9)(p12q21)
B76 Normal 13, 18, 21, X, Y 46,XY,t(1;7)(p36.3;p13)
A1-A4 Trisomy 21 (21R = 1.38 to1.52) 47,XX,+21 Amniotic fluid
A5-A9 Trisomy 21 (21R = 1.38 to1.53) 47,XY,+21
A10-A11 Male with extra X (XR = 0.85, YR = 0.51) 47,XXY
A12 Normal 13, 18, 21, X, Y 46,XY
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Figure 3 The male fetus with trisomy 21 and XXY were analyzed with array-MLPA. The left figures showed the relative signal of each
probe. The probes on chromosomes 13, 18, 21, X and Y were depicted in yellow, blue, green, purple and purplish red, respectively. Eight
autosomal control probes were shown in grey. The right figures showed the average copy numbers on each chromosome. Error bars
represented the corresponding SD of the copy numbers on the MLPA probes covering each chromosome. The copy number of each
chromosome was listed in the tables.
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suitable for detecting mosaicism of monosomy than
polyploidy.
In addition to X chromosome aneuploidies, unknown
marker chromosomes in four cases (B5, B6, B8 and B9)
were found by karyotype analysis, but G-banding did
not distinguish their origins. Finally, we identified the
regions of these unknown marker chromosomes by
array-MLPA. Two of the four cases were confirmed by
Y-chromosome-specific PCR. In another case (B7),






Normal control 85 1 86 0/86 (0%)
Nonmosaic
aneuploidy
69 11 80 4/80 (5%)
Mosaic aneuploidy 7 0 7 0/7 (0%)
Total 161 12 173 4/173 (2.3%)
Figure 4 Array-MLPA analysis of chromosome X monosomy mosaicism. (A) A female patient (B10) with mosaicism. The average copy
number on chromosome X was 0.71. (B) G-banding analysis revealed the patient had the karyotype 45,X/46,X,i(X)(q10). (C) A female patient (B11)
with mosaicism. The average copy number on chromosome X was 0.72. (D) G-banding analysis revealed the patient had the karyotype 45,X
(70%)/47,XXX (30%). Error bars represented the corresponding SD of the copy numbers on the MLPA probes covering each chromosome.
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abnormality on the Y chromosome was identified by
both array-MLPA and G-banding analysis. In this study,
we designed ten pairs of probes to cover the long and
short arms of chromosome Y. The data obtained on
array-MLPA and PCR analysis indicate the presence of
Y chromosome-specific probe signals, especially TSPY
probes. Our study demonstrates the power of array-
MLPA for detecting small abnormalities on
chromosomes.
However, four samples with chromosome transloca-
tions or inversions were not identified by array-MLPA
since the recombination regions were not covered by
Figure 5 Array-MLPA analysis of chromosome X monosomy patients with unknown marker chromosomes. (A) Strong hybridization
signals for TSPY were detected in sample B6. (B) Positive signals for RBMY and TSPY were found in sample B7. (C) PCR analysis of RBMY, SRY and
TSPY detects the unknown marker chromosome detected with G-banding analysis. (D) The unknown marker chromosome in the sample B6 was
derived from chromosome Y.
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the MLPA probes. Currently, we have only used one
(Cy5) of the four available detection wavelengths for
screening chromosomes 13, 18, 21, X, and Y. Using
three additional sets of amplification primers, each
labelled with a different fluorophore [32], it should be
simple to expand the number of MLPA probes for other
chromosomal abnormalities with potential clinical sig-
nificance. Still, array-MLPA cannot completely replace
conventional cytogenetic analysis. It is suitable to be
used as a screening test in conjunction with karyotype
analysis for diagnosis.
Conclusions
Our study demonstrates the successful application of
array-MLPA for clinical molecular diagnosis with rapid
and sensitive screening for chromosomal aneuploidies.
Furthermore, we have developed a simple and rapid
procedure for screening copy numbers on chromo-
somes 13, 18, 21, X, and Y using array-MLPA. Since
array processing and data analysis are fully automated,
array-MLPA should be suitable for large scale testing
for chromosome aneuploidies in clinical diagnostic
settings.
Additional material
Additional file 1: Table S1: Probe sequence for chromosomal
aneuploidy
Additional file 2: Figure S1: Schematic depiction of the array
technology. (A) Four-well array system was used in the study. Each array
contained 412 spots, and the oligonucleotide was immobilized on an
aluminum-oxide substrate. The substrate had a thickness of 60 μm with
long capillary pores. The diameter of an individual pore was between
100 and 200 nm. A single spot occupied about 100,000 pores of the
substrate. (B) Raw image obtained on an array. These images were
recorded at 500 ms, 1000 ms, 1500 ms and 3000 ms exposure time
using a Cy5 filter set. This array design contained 120 probes spotted in
duplicate (240 spots), including 116 universal tag-probe oligonucleotides
for different chromosomes, two exogenous target ArrayControl RNA
Spikes (AM1780, Ambion, Austin, TX) oligonucleotides used as a negative
control for array hybridization, and two Cy5-reference oligonucleotides.
Additional file 3: Table S2: Gene copy numbers on array-MLPA in
normal controls
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